Design of Peptidomimetic Based DPP-IV Inhibitors, Devoid of CYP Liabilities

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|9|9|867-873

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.9, Iss.9, 2012-11, pp. : 867-873

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

De Novo Design of High Potent DPP-IV Inhibitors Based on the Scaffold of Cyanopyrrolidine

By  

Letters in Drug Design & Discovery, Vol. 12, Iss. 6, 2015-07 ,pp. : 479-487

Bentham Science Publishers

Access to resources Recommend Favorite

Aromatic Heterocycle-Based DPP-IV Inhibitors: Xanthines and Related Structural Types.

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 569-578

Bentham Science Publishers

Access to resources Recommend Favorite

11 Years of Cyanopyrrolidines as DPP-IV Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 579-595

Bentham Science Publishers

Access to resources Recommend Favorite

DPP-IV inhibitors could be cost-effective for T2DM

By  

Inpharma, Vol. 1, Iss. 1642, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

DPP-IV inhibitors could be cost-effective for T2DM

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 556, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite